- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02943824
Machine-learning Optimization for Prostate Brachytherapy Planning (MOPP)
Machine-learning Optimization for Prostate Brachytherapy Planning (MOPP): a Randomized-controlled Trial Evaluating Dosimetric Outcomes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Outline:
Traditionally treatment planning for prostate Low-Dose-Rate (LDR) brachytherapy has relied on manual planning by an expert treatment planner. This process involves the planner selecting the location of 80-110 small, radioactive seeds within the prostate; the goal of this process is to maximize the amount of radiation delivered to the cancer while minimizing radiation to healthy tissues, all while making sure the seeds are implantable by the physician. Although this process is effective it is time-consuming (taking anywhere from 30 minutes to several hours to plan).
Machine learning (ML), a form of statistical computation that relies on historical training information to adapt and predict novel solutions, has significant potential for improving the efficiency and uniformity of prostate LDR brachytherapy. The ability of this algorithm to mimic several features demonstrated by expert treatment plans has been difficult to perform using conventional computer algorithms and is a significant advantage. It is expected that by implementing an ML program in the planning workflow for prostate LDR brachytherapy it is possible to significantly decrease the planning time, while improving the uniformity of plan outcomes, and maintaining comparable quality to human planners.
This study will evaluate whether a computer program based on machine learning (ML) can be used to maintain plan quality in prostate LDR brachytherapy that is not inferior to manual planning by a human expert. In addition, it is expected that planning time may decrease to only a few minutes using ML planning.
What Will Happen:
If you decide to participate in this study your first visit will involve an ultrasound study of your prostate to map out the treatment area. After your initial visit for ultrasound imaging nothing further is required on your part for the purposes of the study.
Your images and treatment information will then be used to create a brachytherapy treatment plan by both a human planner, and one by an ML program. Only one treatment plan from one of these groups (a process known as randomization) will be used, your treating physician will not know where your plan came from (a process known as blinding). Your physician will examine the plans, grade its acceptability, and make modifications to it if needed. This final plan will be used to deliver your brachytherapy.
Follow-Up Visits:
You will have a follow-up study approximately 1 month after your brachytherapy treatment. The purpose of this study is to gauge how well your brachytherapy was delivered.
For the follow-up study you will have a CT scan to show the area that was treated (the prostate gland). No further action is required on your part.
Length of Study Participation:
Your participation in this study will after your follow-up visit, approximately 1 month after your brachytherapy treatment.
A total of 42 patients will be enrolled in this study from the Odette Cancer Centre.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N3M5
- Sunnybrook Odette Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed low- or intermediate-risk prostate cancer patients opting for I-125 LDR brachytherapy at the Sunnybrook Odette Cancer Centre.
- Prostate volume on TRUS < 60 cc.
- Ability to give informed consent to participate in the study
Exclusion Criteria:
- Locally advanced or metastatic disease.
- Prior Trans Urethral Resection of the Prostate (TURP).
- International Prostate Symptom Score (IPSS) > 18
- Patients receiving salvage or boost treatments after primary external radiation or brachytherapy.
- Patients on study protocols with prescription doses other than 145 Gy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Machine Learning Planning
Patients will be pre-operatively planned using a machine-learning computer program.
An expert radiation oncologist will evaluate the plan prior to implantation.
The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
|
The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
|
|
Active Comparator: Radiation Therapist Planning
Patients will be pre-operatively planned manually by an expert radiation therapist (> 60 cases planned).
An expert radiation oncologist will evaluate the plan prior to implantation.The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
|
The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
post-operative prostate V100%
Time Frame: 1 month
|
After receiving treatment patients are discharged.
Over the coming month prostate edema decreases.
Approximately 1 month following treatment patients have a CT scan and the plan dosimetry is re-computed from actual radioactive seed positions.
One of the key dosimetry metrics used to assess the quality of the outcomes is the prostate V100%.
This metric will be compared between ML and RT groups.
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pre-operative planning time
Time Frame: 1 min to 1 hour
|
During initial planning of brachytherapy the total planning time required for each case will be compared between ML and RT groups.
|
1 min to 1 hour
|
|
Pre-operative dosimetry
Time Frame: 1 min to 1 hour
|
Along with planning time the final dosimetry of the preoperative plan will be compared between ML and RT groups.
|
1 min to 1 hour
|
|
Frequency & magnitude of plan modifications
Time Frame: 1-5 min
|
During physician QA of both ML and RT plans the time, and magnitude of any plan modifications will be captured and compared between the two groups.
|
1-5 min
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ananth Ravi, PhD, Toronto Sunnybrook Regional Cancer Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1.1.1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
T.O.A.D. Oncology SARecruitingMetastatic Castration-Resistant Prostatic CancerAustralia, France, Canada, Spain, United States
-
MacroGenicsCompletedProstate Cancer Recurrent | Immunotherapy | Androgen-Independent Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic Cancer | Immune Checkpoint Inhibitor | Androgen-Independent Prostatic Neoplasms | Androgen-Insensitive Prostatic Cance | Inhibitory Checkpoint MoleculeUnited States, Spain, France, United Kingdom, Belgium, Australia, Georgia, Bulgaria, Poland, Puerto Rico
Clinical Trials on Machine Learning Planning
-
Brigham and Women's HospitalNational Institute on Aging (NIA); Atrius HealthCompleted
-
UNC Lineberger Comprehensive Cancer CenterAgency for Healthcare Research and Quality (AHRQ)Not yet recruitingCancer | Prostate CancerUnited States
-
Brigham and Women's HospitalNational Institute on Aging (NIA); Boston Medical CenterCompletedDiabetes Mellitus, Type 2 | Medication AdherenceUnited States
-
London North West Healthcare NHS TrustImperial College LondonActive, not recruiting
-
University Hospital TuebingenMax-Planck-Institute TuebingenUnknown
-
Guy's and St Thomas' NHS Foundation TrustKing's College Hospital NHS Trust; Imperial College Healthcare NHS TrustNot yet recruitingHeart Failure | Pacemaker-Induced Cardiomyopathy | Pacemaker ComplicationUnited Kingdom
-
Duke UniversityUniversity of California, San FranciscoCompletedChemotherapeutic ToxicityUnited States
-
ChronolifeUnknown
-
Kepler University HospitalCompleted